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Caveat emptor: direct-to-consumer supply and
advertising of genetic testing
Roxanne Mykitiuk, BA, LLB, LLM

Osgoode Hall Law School, York University , Toronto,
Ont.
Clin Invest Med 2004;27(1):23-32.

Most Canadians who wish to access genetic diagnostic and susceptibility tests do so through the publicly
funded health care system. 1 However, some genetic
tests are not covered under that system, and individuals may seek to purchase them from private
sources. The Internet has become both a vehicle for
advertising and a means to convey Canadians to private genetic testing sources. Usually, people are directed to international providers,2 but in the case of tests for a number
of conditions such as breast and ovarian
cancer they are also directed to local private laboratories such as the multi-city
branches of MDS Laboratory Services,
whose home office is in Toronto.
Normally, people interested in accessing genetic testing services must do so
through a physician who may order the
test. However, a few companies market
their genetic testing products and services
through direct-to-consumer (DTC) adver- Ms. Roxanne
tising, enabling patients to bypass physician involvement. 1 In Canada, the perceived desire
for access to genetic tests outside the public system
is not only exploited but promoted through Internet
availability. In the United States, DTC marketing of
genetic testing through print and broadcast campaigns has begun, which contributes to the perceived
desire for such testing. For example, in the fall of
2002, Myriad Genetics, Inc. (Myriad) began a DTC
advertising campaign for its product BRACAnalysis
(which tests for risk of breast and ovarian cancer) in
both print and broadcast media.
The surge in recent advances in human genetics
has fostered a trend towards commercialization, just
as commercial interests have contributed to the

recent advances in genetics: universities and government research centres frequently seek collaboration
with (and funding from) private genome research
companies, which in turn increasingly are developing
cooperative relationships with pharmaceutical companies.3In the context of DTC adve1tising and supply
of genetic testing services, this raises concerns about
the type of information that is provided
to "consumers" through the commercial
market. 4 Companies who manufacture
products necessarily participate in the
creation of consumer demand, precluding
the provision of consumer information
that is unbiased and sufficient. Irrespective of the fact that DTC marketing effectively sidesteps physician involvement,
there is also some question as to whether
physicians themselves possess a level of
knowledge adequate to comprehend these
genetic tests and explain their import to
Mykitiuk their patients.
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In the absence of any meaningful regulation restricting DTC advertising of genetic testing
services, Canada is likely to witness an increase in
print and broadcast advertising of genetic testing
similar to the marketing campaigns now being
launched in the USA. This article therefore has 4
intents:
1. to highlight the major players and targeted consumers in the realm of private access to genetic testing and DTC advertising
2. to canvass arguments for and against private access to commercially available genetic testing
3. to analyze the recent DTC campaign by Myriad
as an example of what may be on the horizon for
Canada
23
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4. to question the adequacy of Canada's current regulatory system to deal with advertisements of this
nature and, by examining the routes taken in other
jurisdictions, to explore the potential for an improved regulatory framework specific to genetic
testing services

Access to commercial testing services for
genetic susceptibility
Currently, Canadians access genetic testing primarily
through the public health care system. Patients typically visit their family physician; given a clinical presentation or family history suggestive of an inherited
condition, they are then referred to a genetics department in a hospital or cancer agency for genetic counselling.1 In Ontario, 9 linked regional genetics centres
in Hamilton, Kingston, London, Mississauga, North
York, Sudbury, Oshawa, Ottawa and Toronto operate
as a genetics network for the province.5 In November
2001, base funding for the Provincial Regional Genetics Program in Ontario was $39 million.5 In light
of the rapid growth in genetic testing capabilities, significant deliberation has been given to instituting a
framework for the evaluation of public coverage of
predictive genetic tests and services. To this end, the
Ontario Provincial Advisory Committee on New Predictive Genetic Technologies' recommended the
assessment of 6 key factors in determining whether a
particular genetic test will be granted provincial coverage: technical accuracy; clinical effectiveness; usefulness to tested individuals; adverse and additional
effects; expansion potential; and cost.
Even if this comprehensive evaluation scheme is
implemented, not all useful genetic tests will be covered by provincial health insurance plans. Moreover,
access to government-funded tests will be limited to
those individuals considered by their physicians and
the referral centre to benefit clinically from testing.6
Not all individuals who seek genetic testing will be
able to access it. And whereas some people may feel
relieved to be told that that they do not need genetic
testing, others may feel neglected, fearful or anxious,
and will turn to private options. 1 Similarly, the "motivated consumer" with access to the Internet will
soon discover the quick and accessible testing services that can be purchased privately.7-8
24
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At present, only a handful of private Canadian laboratories offer genetic susceptibility testing for adultonset condilions. Most Canadian companies focus
their genetic interest instead on paternity testing
(e.g., Helix Biotech) and pre- and post-natal diagnostics (e.g., Procrea). Although there are still few
commercial genetic testing laboratories in the United
Kingdom, the growing availability of genetic testing
has prompted Britain's Human Genetics Commission to devise a thorough study of oversight (i.e., the
regulation) of direct genetic testing. 9 Public demand
for direct genetic testing services was found to be
fairly low: over 60% of those surveyed stated that
they were "unlikely" or "very unlikely" to use home
genetic testing. On the other hand, 81 % responded
that they would consider genetic testing if offered by
their physician.
In contrast, many more American companies have
been involved in genetic testing; in 1996, there were
"approximately 200 laboratories providing 175 OOO
genetic tests for over 300 diseases or conditions in
the USA." 9 Although the majority of these tests are
marketed to medical professionals, DTC advertising
and supply is on the increase. Hundreds of commercial Web sites now direct consumers to companies
that provide paternity testing, DNA "fingerprinting"
or pre-natal testing, most based in the USA.1 There
are also companies in Canada and Europe that provide access to testing over the Internet. Of these Web
sites, a dozen or so also direct consumers to adult
genetic susceptibility testing companies, and 4 offer
DTC genetic testing services themselves. 2 Increasingly, because of the "global marketplace" created
by the Internet, provincial and national borders are
becoming irrelevant.
DTC genetic testing is possible because of the relative ease with which genetic material can be retrieved for laboratory analyses. 1 In most cases, tests
are done on samples collected through non-invasive
means such as mouth swabs or saliva samples. Most
laboratories make the process even easier for customers by providing containers and detailed instructions for obtaining, packaging and shipping the samples, as well as referrals to local affiliated clinics if a
blood sample is required. Payment for testing, either
DTC or privately purchased but mediated by a
physician, may be billed to a credit card through a

j
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secure Web site or paid by a third party such as a private insurer. 1

Arguments in favour of direct-to-consumer
supply of genetic testing
A prime attraction for consumers of private genetic
testing services, and one that marketing campaigns
target specifically, is the potential for enhanced privacy and individual control of genetic information. 10
Patients can order tests online without having to meet
the criteria required to obtain them through a physician's office. 1 Also, as test results can be received at
home, they are not automatically entered into medical
records and therefore can be kept hidden from insurers or employers. 1 This may be a significant incentive
for consumers, especially in the United States where
the link between employment status and health insurance makes genetic discrimination a concern. 11
However, it should be noted that some jurisdictions
have implemented and many others have recommended the implementation of regulations or legislation
to avoid discrimination in the context of insurance. 12
The privacy argument may have less weight in
Canada and other countries where health coverage is
provided universally regardless of one's health or
employment status, although concerns about life insurance may remain. 1 Where a test is not covered under a public health care system, genetic info1mation
may be desired nonetheless and considered worth
paying for, out of pocket. 13 Although a specific genetic test may not be covered because of a lack of evidence for clinical effectiveness, 1 consumers may
have other motives to seek testing, including to reduce anxiety; to facilitate life planning; to initiate
family discussions of issues such as social and psychological support and responsibility to and for other
family members; and to help people plan career
changes. 13- 15
A prominent argument in favour of DTC supply of
genetic tests is consumer autonomy. Proponents of
this view argue that the ability to obtain information
about oneself, including information about one's
potential risk of disease, is an individual right that
should be restricted only in cases where the interests
of others might be harmed. 9 This view is consistent
with the shift from paternalism to individual self-

dete1mination that characterizes current approaches
to health care and underpins many of the arguments
in favour of DTC advertising and supply of genetic
testing services. 16
Other potential benefits include better-informed
consumers, which may lead to superior quality of
care stemming from improved diagnosis; to better
matching of therapy needs to the preferences of patients; and possibly to enhanced compliance with
treatments. 11 Similarly, ads for genetic tests targeted
directly to the public may have educational value if
the information they provide is scientifically accurate. Such advertisements may provide relevant information about testing that could lead to therapeutic
interventions or increased disease surveillance. They
may also raise awareness of community resources
such as associations and support groups for those
dealing with various genetic diseases and predispositions, and of options for parents and potential parents about reproductive alternatives and screening
tests for newborns. 18 Nevertheless, profit-driven education is inherently suspect, and the public can be informed and educated by more trustworthy means.

Concerns about the direct supply of genetic
testing services
Genetic testing provides information that is often
complex and difficult to understand; nevertheless, it
may profoundly affect a person's sense of self and
have important implications for family members. Patients who, in the estimation of their physicians, do
not need or are unlikely to benefit from genetic testing may nonetheless be influenced by marketing that
plays on or increases anxiety, and may be harmed by
the resulting genetic information. 19·20 Misunderstandings about risk estimations, how the information
should be integrated into a one's life, and what to explain to family members are frequent. 2122
Consumers may gain a false sense of security from
negative test results, spend limited financial resources
on testing that could better be used elsewhere, or become unnecessarily anxious about risk for disease.23
Furthermore, individuals who have misunderstood
information from genetic tests, received incorrect information or misinterpreted predictive health information could consequently make poor health-related
Clin Invest Med • Vol 27, no I, February 2004
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decisions, such as delaying seeking medical advice,
seeking inappropriate medical treatment, or making
expensive and unproven lifestyle or dietary changes. 9
The risk of both physical and psychological harm
thus justifies consumer protection relating to both the
advertising and supply of health related products.
As much as consumers may desire straightforward
choices and "solid" information, genetics is a complex and rapidly changing area. Cancer itself has a
great many contributing factors beyond inherited
genes, and the interactions are complicated and often
unclear. The risks and uncertainties associated with
genetic information are difficult for many physicians
to grasp, 18 let alone the general public. DTC advertising of tests enables genetics companies to take
advantage of peoples ' incomplete understanding of
genetics and exploit their worries about their and
their family's health and future. Advertising in general plays on the emotions of the target audience and
can not provide the type of information that consumers need to make informed decisions, particularly
about pharmaceutical and genetic products. 24
False positives and false negatives constitute another concern. Currently there is little or no professional consensus in the scientific community about
the clinical value of many genetic tests. For example,
the BRACAnalysis test for breast and ovarian cancer
was put on the market despite disagreement on the
test's "appropriateness" at the time. 18 It is a consequence of commercialization that commercial pressures become the leading reason for the entrance of
items into the marketplace, which may lead to the
introduction of health care products prematurely.4
In addition, inadequate opportunities for qualified
genetic counselling may leave patients psychologically unprepared to deal with the genetic information
they do receive. Genetic counselling for patients and
families undergoing genetic susceptibility or diagnostic testing has become the standard of public
health care in Canada, but only a few private companies provide or require counselling as part of their
genetic testing services.
Given the current shortage of genetic counsellors,
it will most likely be family physicians who will receive requests for access to private testing. They may
have to interpret advertisements for interested patients, explain why tests may be inappropriate 17 and
26
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provide additional counselling. This increase in
workload will add to their stress, with serious consequences for their patients. Time constraints may
limit the effectiveness of their counselling, and many
family physicians will not have had the necessary
background in genetics, let alone specific training
in counselling, to provide and interpret test results
and help patients understand the complex scientific,
social and psychological issues. 25 Nor is it likely that
physicians will have had the training to evaluate the
validity of claims made by industry about the accuracy and benefits of testing. 26 Thus, many family physicians may be open to the influence of companies'
marketing strategies and unable to effectively criticize the information they receive, as has been argued
with respect to prescription drugs. 27 28
DTC advertising and supply of genetic tests also
raises concerns about strains on the financial resources of the health care system and has implications
for equal access to health care services. Inappropriate demands by patients for genetic testing can burden public health funds; so can post-test costs such
as counselling, follow-up of results and associated
treatments-all of which are likely to be covered
under the public health care system. 29
Access to and cost of genetic tests through public
health care systems are controlled by the patent owners, who legally control access to and development
of any type of test, treatment or cure that uses the
patent. For example, Myriad Genetics, Inc., owner of
the Canadian patents for the BRCA 1 and BRCA2
genes linked to hereditary breast cancer, is attempting
to enforce its gene patents and oblige public agencies
to provide BRCA testing exclusively through use of
its BRACAnalysis test. 1
Myriad's monopoly over the BRCAl and BRCA2
genes illustrates the growing phenomenon of biotechnology companies patenting the development,
marketing and provision of genetic tests and therapeutics. Public health care systems like Canada's
could lose the ability to provide coverage for many
types of genetic testing, since companies are driven
to market their gene-based diagnostic products and
therapeutics in a restrictive and costly fashion to recoup their research investments. 1
There are also serious concerns about the safety,
accuracy and quality control of commercial genetic
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tests. Regulatory agencies and oversight mechanisms
are in place in the USA, Canada and other countries
to inspect national laboratories and to review staff
and technical qualifications. But even when present,
these review mechanisms may be implemented by
agencies that are understaffed and under-resourced,
and able to respond only afte1ward to serious breaches
in standards. 8 Because the Internet allows companies
to cross national borders, using the Internet as a marketing and delivery mechanism enables testing providers to avoid being subject to the national regulatory regimes of a consumer's home country. Since
there are as yet no international regulations for genetic testing facilities, consumers will be unlikely to
know if a given provider is meeting their local standards for safety and accuracy. 1
Ontario's health care system facilitates quality assurance in genetic testing by integrating pre-test
preparation, laboratory analysis and interpretation
into clinical practice, along with support consultation about test results. 5 The standards used by professionals and institutions when delivering other services will apply to the provision of genetic testing and
ancillary services integrated into Ontario's public
health care system. Since the procedures of private
laboratories are not transparent, there is no guarantee
that they are implementing standards of quality assurance or confidentiality.
In response to some of these concerns a number of
Internet health service providers (not specifically
genetic testing companies) have attempted some
form of self-regulation. For example, some providers
have chosen to adopt codes of ethics, such as the
e-Health Ethics Initiative, Draft Code or the HON
Code of Conduct for Medical and Health Web Sites
(www.ihealthcoalition.org/ethics/ehcode.html and
www.hon.ch/HONcode/Conduct.html, respectively), that include guidelines about protection of privacy, quality, authority and accuracy of information,
and transparency of interests. 1
Such efforts at self-regulation may convince legislators that overt regulation is unnecessary; however
more formal regulation and oversight is advised, particularly in the area of genetic testing services, to protect consumer privacy of personal health information
and to ensure the accuracy of marketing claims and
efficacy of tests. Given the international scope of

commercial health care provision, national governments must also work toward harmonizing regulation and oversight mechanisms. 1

An example of DTC marketing of genetic
susceptibility testing: the Myriad campaign
Myriad's DTC advertising campaign for breast cancer testing, which included both broadcast and print
media, was piloted beginning September 13, 2002 in
Denver and Atlanta. According to Myriad's press
release, the "campaign is designed to alert women
with a family history of cancer to recent advances in
cancer prevention and early disease detection. lt is no
longer appropriate for these women to simply consider breast cancer their destiny, even in the context of
a strong family history of the disease." Myriad goes
on to say that "medical interventions have been
shown to be effective in lowering the risks of cancer
in individuals [with a family history of the disease] ."
Whereas their earlier marketing and educational efforts had been aimed toward cancer specialists, they
state that there is now a need to "reach those with a
family history of breast or ovarian cancer who do not
themselves have cancer," because this group of individuals "stands to benefit the most" from this tool of
predictive medicine.
The broadcast ad features several women each stating their concern about breast cancer and the benefits
of taking a BRACAnalysis test. They appear calm
and in control, as if the knowledge they have gained
from taking the test has made them more confident.
Toward the end of the minute-long advertisement, a
woman's voice explains that BRACAnalysis "can
help you see the big picture."
The ad is notable in several ways. First, it features
women of visibly diverse racial origins, almost all
apparently between the ages of 30 and 45. The campaign is aimed at women between the ages of 25 and
54 and targets major cities with large minority populations: Hispanics in Denver and African-Americans
in Atlanta (Sandra Blum, BRACAnalysis Project
Manager, Myriad Genetics, Inc., Salt Lake City,
Utah: personal communication, 2002 Oct. 21). To
achieve the broadest potential market Myriad is
clearly attempting to demonstrate that the risk of
breast cancer cuts across the population . Moreover,
Clin Invest Med • Vo! 27, no 1, February 2004
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by targeting relatively young women in their thirties
and early forties, the campaign is attempting to capture women with significant disposable income, at
an age when they are making important choices
about career and family life. The BRACAnalysis
Integrated Awareness Campaign ran for 5 months
and included ads broadcast during major television
shows, including ER, The Practice, CSI: Miami,
Providence, Oprah, Regis and Kelli, and The Today
Show. In addition, print advertisements ran in regional versions of publications such as Better Homes
and Gardens, The Ladies' Home Journal and
Women's Health Monitor. The choice of many of the
marketing venues indicates an attempt by Myriad to
target a demographic of women who already have a
general interest in issues relating to health and wellbeing.
Second, the fact that the ad never uses the words
"gene" or "genetic" but instead talks about "family
history" implies to viewers that BRACAnalysis can
identify individuals at risk for heritable forms of
breast cancer. This is a sweeping and exaggerated
claim: BRACAnalysis can only identify 2 genetic
mutations associated with about 7 % of all breast
cancers. 1n
Third, the ad suggests that a woman who takes the
test will be able to "reduce her risk through effective
medical options," but these options are never identified. Instead, the ad cultivates an overall impression
that taking "a simple blood test" will enable the
viewer to reduce her risk of breast cancer. The uncertainties of genetic testing are downplayed, and the
lack of professional consensus on the clinical validity and efficacy of the test goes unmentioned. The
symbolism of the "big picture" theme that pervades
the ad covertly implies that the advertisement is providing thorough and unbiased information.
Fourth, the ad cleverly plays on 2 common themes
often used in pharmaceutical advertising. 31 On the
one hand, the ad promotes the idea of interventionist
medicine, which places a high value on action while
rejecting the "wait and see" model of health care. 31
Traditionally, the "Lake-action" approach to health
care refers to the notion of physician control. This
emphasis on medical intervention creates a chain between manufacturer, advertisement and doctor, with
the ultimate profit going to drug companies or, in
28

Med clin exp • vol 27, n° 1, fevrier 2004

this case, genetics testing companies.' '
On the other hand, by advertising BRACAnalysis
directly to the consumer, Myriad introduces the secondary concept of "participatory and autonomous
roles in the context of medical decision-making." 31 In
drawing on the theme of "choice," Myriad's ads
"validate patients ' worries about their genetic risks
and appeal to their desire to assert control over potential outcomes." 18 This encourages the move away
from the paternalistic doctor-patient relationship and
stresses the consumer's right to gain knowledge
about their own risk for disease and hence their right
to be in control.
Interestingly, the voice-over at the end of the broadcast ad states "Talk to your doctor," which seems to
dismiss the notion of consumer autonomy. Conversely, this statement gives viewers the impression
that physicians will corroborate the "information"
from the ad, and grants patients who have decided to
undergo BRACAnalysis testing the reassurance that
they are making the proper choice. Thus, the advertisement conveys the notion that the medical profession does not have a monopoly on knowledge about
our bodies, and reinforces the notion that patients will
reap a benefit from choosing to act autonomously
and get a genetic test.
Fifth, contrary to Myriad's claim that BRACAnalysis
is the tool of choice for women to reduce their risk
of breast cancer, the ad's repeated use of the words
"risk" "choose" and "ready" demonstrates that the
campaign's true purpose is to heighten the perception of risk of cancer among a broader segment of
women than would be identified through physician
advice or evidence-based medicine. Playing on
women's fears and suggesting that all women are at
risk is a common feature of DTC pharmaceutical advertising.32
Overall , there is little doubt that the main objective
of the ad campaign is to target women and to bypass
the role of physicians as the gate-keepers of medical
knowledge, despite claims to the contrary that it is
an "integrated" campaign addressed both to physicians and to women with a family history of the disease. Interestingly enough, the product manager for
BRACAnalysis indicated that the campaign was
aimed at women because they are known to be the
managers of health care in the family and not just
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because the incidence of breast cancer is much
higher in women. Just days into the campaign,
Myriad cited with pride the 40 phone calls a clay
received on their toll-free number as a direct result
of the campaign. 11
Myriad asserts that since physicians are not adequately informed about genetics and testing, a DTC
advertising campaign is warranted to educate consumers so they can make better health-care decisions. There is some credibility to this argument in
private systems like that of the United States, where
no governing public body bears the responsibility for
promoting consumer awareness and undertaking
health education programs. In Canada's public
health systems, this responsibility lies with provincial health departments; in Britain's, with the National Health Service. The danger is that the information provided is motivated by market incentives
and is thus is not primarily designed to educate.

Current regulations of DTC supply and
advertising of genetic testing in Canada
The advertising of pharmaceutical drugs and medical devices in Canada is governed by the Food and
Drugs Act33 and the Broadcasting Act, 34 but there is
nothing in these Acts or their regulations that would
prohibit or regulate DTC advertisements of genetic
testing similar to Myriad's campaign in the USA.
The Food and Drugs Act prohibits advertising to
the public of any food, drug, cosmetic or device as a
treatment, prevention or cure for a number of diseases indicated in a schedule in the legislation. 33 A
"device" is any article, instrument, apparatus or contrivance that is manufactured, sold or represented for
use in the diagnosis, treatment, mitigation or prevention of a disease. 33
It is uncertain whether a device, as defined, includes
commercial genetic test kits, since the uses listed
may not fully describe the purpose of a genetic test
such as the BRACAnalysis product. The Medical
Devices Bureau, an agency enabled by the Medical
Devices Regulations and the Food and Drugs Act, is
responsible for issuing licences to manufacturers to
sell medical devices in Canada. Sections 26 and 27
of the Medical Devices Regulations control the advertising of products that fall under Class UI, mean-

ing they present a moderate risk in terms of public
health implications. 35 These provisions indicate that a
licence must be held in order to sell genetic tests, and
that if they are advertised there must be a warning
stating that they may not have been licensed in accordance with Canadian law. Before the product is available for sale in Canada, a pre-market review is done,
at which time a genetics company will attempt to obtain a licence by satisfying safety effectiveness and
clinical standards. Advertising is a post-market activity under the mandate of the Inspectorate. Identifying
which oversight bodies are expected to regulate DTC
advertising tells only half the story: tight government
resources and pressure in Canada to lift restrictions
on DTC advertising means that the agencies with the
mandate to regulate in this area are having difficulty
doing so. 36
It is important to note that what is actually being
regulated by the aforementioned legislation and regulations are commercially offered genetic test kits that
might be marketed to individuals for their own private use, rather than genetic testing that is offered as
a service. For the most part what is on offer today,
and what consumers are purchasing, are not genetic
test kits but testing services that fall outside the scope
of current legislation.
Furthermore, the content of ads of this nature are
not subject to regulation under the Broadcast Act, but
to a voluntary system of regulation through voluntary
adherence to guidelines established by the Pharmaceutical Advertising Advisory Board (PAAB). An organization of interested groups, including manufacturers, PAAB has developed a Code of Advertising
Acceptance for what they term advertising and promotion systems. The advisory board operates independently of government regulatory structure. The
PAAB Code 37 applies to "all communications in
which claims, quotations and references are made for
single-entity and compound prescription and nonprescription (over-the-counter) pharmaceutical products." Moreover, a pharmaceutical product is defined
as "a substance or mixture of substances manufactured, sold or represented by a specific manufacturer
for in vivo use in the diagnosis, treatment, mitigation
or prevention of a disease, disorder, abnormal physical state, or in restoring, correcting or modifying
function(s) in humans." Again, it is necessary to exClin Invest Med • Vol 27, no 1, February 2004
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amine the purpose of the product put forth by the
manufacturer to determine whether or not it fits into
the PAAB Code's definition and is thus subject to
regulation. It is questionable whether genetic tests
will ever fit this definition.
An examination of how DTC advertising and supply of genetic testing is regulated in other countries
identifies paths Canada could follow in developing
its own regulatory scheme.

Future regulatory framework: ideas from
other jurisdictions
The British Human Genetics Commission found that
in the United Kingdom there was a general interest
in placing restrictions on advertising of DTC genetic
testing. Many of the Commission's general recommendations on DTC advertising and supply of genetic testing are pertinent to the develoment of a regulatory scheme for Canada.
Current controls on genetic testing in the United
Kingdom include the Advertising Standards Authority, which administers the British Codes of Advertising and Sales Promotion. Many of those participatei n g in the Commission's study supported
strengthening the Codes, especially in relation to direct genetic testing services, which could take the
form of an additional section in the Codes with specific requirements. 9 The report stated that most genetic tests that provide predictive health information
should not be supplied directly to the public or
through a non-medical health professional such as a
pharmacist. For direct genetic tests to be provided
over-the-counter, a manufacturer would have to
"convince a regulator that the test is sufficiently well
validated and that anyone involved in providing the
test has the right training and expertise to give good
quality advice to the consumer," 9 an approach that
resembles the way medicinal products classified as
"pharmacy-only" are regulated.
In the United States, both the Food and Drug Administration and the Federal Trade Commission have
roles to play in monitoring advertisements of genetic
tests, yet neither has exercised their authority in this
area. 18 Some suggest that "shared oversight" of DTC
advertising of genetic testing by these administrations
would help ensure that advertisements provide infor30
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mation about the risks as well as the benefits of using
genetics tests and avoid hyperbolic statements about
their effectiveness. 18 After the Myriad campaign, the
Centers for Disease Control and Prevention also
launched a study similar to that of the British Commission to investigate the effects of DTC advertising
of genetic testing.
Regardless of the regulatory mechanisms put in
place for the advertising and supply of genetic testing, Canadians will remain exposed to advertising
through American and internationally based Web
sites- thus the additional need for Internet regulation. The CRTC has already stated that it will have no
role to play in the development of regulations for the
Internet. 1
While ideas from other jurisdictions may prove to
be instructive, to understand the full implications of
DTC advertising of genetic testing the particulars of
Canada's health care system must be considered.
Canada's "ad hoe nature of decision-making and
diversity [of] service coverage within provincial
health-insurance plans" may mean that OTC advertising will be especially effective, since beneficial
genetic services might not be covered consistently
across Canada (Bryn Williams-Jones, '"Be ready
against cancer, now': Myriad Genetics' direct-toconsumer advertising campaign," currently under
peer review; on file with RM.). Moreover, given the
existence of the global marketplace, the choice of
regulatory framework will be conditioned not only
by federalism but also by Canada's obligations under
and participation in various international trade agreements.

Conclusion
Private genetics companies seek new and expanded
markets in which to sell their products. Increasingly,
jurisdictions have become targets of DTC advertising
campaigns marketing genetic tests. The concern is
that this trend will soon penetrate the Canadian market as well. Without proper and thorough regulation,
the only guiding principle with respect to decisionmaking on genetic testing will be caveat emptor, a
principle strikingly out of place in a health care system structured around physician responsibility and
protection of patient interests.
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The problems explored in this article with respect
to OTC advertising and supply of genetic tests demand further study. We need to investigate possible
regulatory frameworks appropriate to a publicly
funded health care system. If left only to the principle
of caveat emptor, the danger is that a "buyer beware"
mentality will come to characterize the relationship
between physician and patient, subtly transforming
the Canadian health care environment.
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